Drug Pricing

Drug Pricing

Sally C. Pipes Explains the Danger of Drug Price Controls with Coronavirus

PRI’s Sally C. Pipes, President, CEO, and Thomas W. Smith Fellow in Health Care Policy, joined the Kirby Nation to discuss the danger of drug price controls and American medical innovation. Pipes explains that roughly 4,500 new drugs are in various stage of development, with an estimated three-quarters of those ...
Commentary

In coronavirus battle, price controls would make it harder to develop lifesaving drugs

As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Blog

What We’re Watching – March 27

Tim Anaya – Escape the Drug Pricing Maze Watch Professor Salvare guide Pete Paystoomuch through the drug pricing maze, showing how the direction policymakers take on drug pricing policy could impact the affordability and availability of current medicines, and innovation that could lead to future, life-saving cures. Ben Smithwick – ...
Drug Importation

New Animated Series Aims to Help Patients “Escape the Drug Pricing Maze”

SAN FRANCISCO – As prescription drug pricing and accessibility has become a greater topic of discussion during the current coronavirus pandemic, a new series of animated videos launched today by the Center for Medical Economics and Innovation at the Pacific Research Institute aims to guide Americans through the “drug pricing ...
Commentary

Coronavirus shows why you don’t want price controls during a pandemic

The World Health Organization has declared the novel coronavirus a global pandemic, with more than 118,000 confirmed cases worldwide. As countries brace for the worst, people around the world are looking to the United States for a drug that can prevent or cure the disease. The world is right to put its ...
Commentary

Just say no to California’s drug-making plan

California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Commentary

Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s

The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
Blog

Newsom’s ‘Bold’ Plan on Prescription Drugs Won’t Really Help Patients, Lower Drug Costs

In a state where the private sector continues to be marginalized in favor of more government, Gov. Gavin Newsom has plans for California to set up a generic drug label of its own. It would be the first state in the country to go into the pharmaceutical business, and will ...
Commentary

Price Controls Impose High Costs On Patients

Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Drug Pricing

Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News

Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Drug Pricing

Sally C. Pipes Explains the Danger of Drug Price Controls with Coronavirus

PRI’s Sally C. Pipes, President, CEO, and Thomas W. Smith Fellow in Health Care Policy, joined the Kirby Nation to discuss the danger of drug price controls and American medical innovation. Pipes explains that roughly 4,500 new drugs are in various stage of development, with an estimated three-quarters of those ...
Commentary

In coronavirus battle, price controls would make it harder to develop lifesaving drugs

As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Blog

What We’re Watching – March 27

Tim Anaya – Escape the Drug Pricing Maze Watch Professor Salvare guide Pete Paystoomuch through the drug pricing maze, showing how the direction policymakers take on drug pricing policy could impact the affordability and availability of current medicines, and innovation that could lead to future, life-saving cures. Ben Smithwick – ...
Drug Importation

New Animated Series Aims to Help Patients “Escape the Drug Pricing Maze”

SAN FRANCISCO – As prescription drug pricing and accessibility has become a greater topic of discussion during the current coronavirus pandemic, a new series of animated videos launched today by the Center for Medical Economics and Innovation at the Pacific Research Institute aims to guide Americans through the “drug pricing ...
Commentary

Coronavirus shows why you don’t want price controls during a pandemic

The World Health Organization has declared the novel coronavirus a global pandemic, with more than 118,000 confirmed cases worldwide. As countries brace for the worst, people around the world are looking to the United States for a drug that can prevent or cure the disease. The world is right to put its ...
Commentary

Just say no to California’s drug-making plan

California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Commentary

Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s

The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
Blog

Newsom’s ‘Bold’ Plan on Prescription Drugs Won’t Really Help Patients, Lower Drug Costs

In a state where the private sector continues to be marginalized in favor of more government, Gov. Gavin Newsom has plans for California to set up a generic drug label of its own. It would be the first state in the country to go into the pharmaceutical business, and will ...
Commentary

Price Controls Impose High Costs On Patients

Twenty-five years ago, the leading cause of death for adults between the ages of 25 and 44 was complications from HIV. At the time, 50,000 Americans were dying from AIDS-related causes a year, with the African American community particularly hard hit – 49 percent of the people dying from AIDS-related deaths ...
Drug Pricing

Wayne Winegarden Drug Pricing Study Featured in Healthcare Finance News

Drug supply chain, pricing system reforms will slash healthcare costs, says PRI By Jeff Lagasse As the Trump administration pushes for price caps and government controls to address prescription drug prices, a new issue brief released by the Center for Medical Economics and Innovation at the Pacific Research Institute contends ...
Scroll to Top